BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8630414)

  • 1. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
    Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
    Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
    Verfaillie C; Miller W; Kay N; McGlave P
    Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.
    Lotzová E; Savary CA; Champlin RE
    J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma.
    Verfaillie C; Blakolmer K; McGlave P
    J Exp Med; 1990 Aug; 172(2):509-2. PubMed ID: 2373991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
    Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE
    Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.
    Bhatia R; McGlave PB
    Leukemia; 1995 Jun; 9(6):1006-12. PubMed ID: 7596165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium.
    Bhatia R; McGlave PB; Miller JS; Wissink S; Lin WN; Verfaillie CM
    Exp Hematol; 1997 Aug; 25(9):980-91. PubMed ID: 9257812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells.
    Heissig B; Pasternak G; Hörner S; Schwerdtfeger R; Rossol S; Hehlmann R
    Leuk Res; 2000 Mar; 24(3):217-31. PubMed ID: 10739004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.
    Agarwal R; Doren S; Hicks B; Dunbar CE
    Blood; 1995 Mar; 85(5):1306-12. PubMed ID: 7532038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo culture of CD34+/Lin-/DR- cells in stroma-derived soluble factors, interleukin-3, and macrophage inflammatory protein-1alpha maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay.
    Miller JS; McCullar V; Verfaillie CM
    Blood; 1998 Jun; 91(12):4516-22. PubMed ID: 9616147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation.
    Lundell BI; McCarthy JB; Kovach NL; Verfaillie CM
    Leukemia; 1997 Jun; 11(6):822-9. PubMed ID: 9177435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.
    Bhatia R; McCarthy JB; Verfaillie CM
    Blood; 1996 May; 87(9):3883-91. PubMed ID: 8611716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages.
    Bhatia R; McGlave PB; Dewald GW; Blazar BR; Verfaillie CM
    Blood; 1995 Jun; 85(12):3636-45. PubMed ID: 7780147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation.
    Verfaillie CM
    Blood; 1993 Oct; 82(7):2045-53. PubMed ID: 7691246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells.
    Verfaillie CM; Miller JS
    Blood; 1994 Sep; 84(5):1442-9. PubMed ID: 7520771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.